In multiple studies, cfDNA has been utilised for monitoring of resistance mutations including EGFR T790M, BRAF, ALK, ERBB2 amplification in NSCLC patients receiving therapy [15,37,41,73,109,128,161,162]. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.